Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
Werewolf Therapeutics develops conditionally activated therapeutics engineered to stimulate the immune system for cancer and other immune-mediated conditions. News about HOWL centers on the company’s PREDATOR platform, INDUKINE molecules, INDUCER T cell engager work, and programs such as WTX-124 and WTX-330.
Recurring updates include clinical and preclinical data presentations, FDA regulatory designations, operating and financial results, program licensing or asset-rights activity, capital-structure actions, shareholder voting matters, and corporate-strategy updates tied to the company’s oncology-focused development pipeline.
Werewolf Therapeutics (NASDAQ: HOWL) has successfully completed its initial public offering, raising $120 million in gross proceeds.
For Q1 2021, the company reported a net loss of $7.4 million, an increase from $3.8 million in Q1 2020. Cash and cash equivalents declined to $84.6 million compared to $92.6 million at the end of 2020.
Research and development expenses surged to $4.8 million, up from $2.8 million in the same quarter of 2020, reflecting the ongoing development of its lead cancer treatment programs.
Werewolf Therapeutics (NASDAQ: HOWL) appointed Mike Sherman, CEO of Chimerix, Inc., to its board of directors, enhancing the company's leadership during a critical growth phase. Sherman brings over 30 years of experience in biotechnology, including a successful tenure at Endocyte, where he led a $2.1 billion acquisition by Novartis. His expertise in corporate strategy and product focus will support Werewolf's advancements in its innovative cancer therapies, notably the WTX-124 and WTX-330 candidates, which are progressing towards clinical development.
Werewolf Therapeutics, a biopharmaceutical company listed on Nasdaq as HOWL, announced that its CEO, Daniel J. Hicklin, Ph.D., will present at the Jefferies Virtual Healthcare Conference on June 3rd at 11 am ET. The company focuses on engineering conditionally activated therapeutics to enhance the immune system for cancer treatment. Their proprietary PREDATOR™ platform aims to create molecules that activate specifically in the tumor microenvironment. WTX-124 and WTX-330 are two leading candidates currently in preclinical studies.
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) announced the pricing of its upsized initial public offering (IPO) of 7,500,000 shares at $16.00 each, yielding approximately $120 million in gross proceeds. An option for underwriters to purchase an additional 1,125,000 shares is also granted. Trading on the Nasdaq Global Select Market begins on April 30, 2021, with the offering closing anticipated on May 4, 2021. The company focuses on developing immunotherapeutics for cancer treatment, leveraging its PREDATOR™ platform.